Skip to main content

Table 3 Characteristics of patients in the independent test set 1

From: Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis

Sample ID Age (years) Sex Bacterial isolation Antibiotherapy before blood collection Underlying diseases Survival
Other sepsis (n = 11)       
   I016* † 61 Female Coagulase-negative staphylococci Ceftazidime, bactrim, Sulperazole Hematemesis Survivor
   I017* ‡§ 50 Male Coagulase-negative staphylococci Ceftriaxone, ceftazidime, doxycycline, cloxacillin Acute pancreatitis, nephrotic syndrome Survivor
   I018§¶¥ 57 Male Coagulase-negative staphylococci# Vancomycin T2D, CRF Survivor
   I019¤ 58 Female Staphylococcus aureus Cloxacillin, ceftazidime T2D, wound Survivor
   I020¶¥ 66 Female Coagulase-negative staphylococci# Ceftazidime, ceftriaxone T2D, ARF, tuberculosis Non-survivor
   I021 54 Female Enterococcus spp. Ceftazidime, cloxacilin T2D, abscess Non-survivor
   I022§¶ 37 Male Coagulase-negative staphylococci# Ceftriaxone, ceftazidime T2D, ARF Non-survivor
   I023¶¤ 70 Female E. coli Doxycycline, ceftazidime T2D Non-survivor
   I024¶¥ 56 Male Coagulase-negative staphylococci Meropenem, ceftazidime T2D, RF Survivor
   I025* 50 Male S. pneumoniae Ceftriaxone, meropenem T2D Non-survivor
   I026 57 Male K. pneumoniae Ceftriaxone, ceftazidime, bactrim T2D Survivor
Septicemic melioidosis (n = 13)       
   M016 39 Male B. pseudomallei Ceftazidime, bactrim, doxycycline T2D Survivor
   M017 52 Female B. pseudomallei Norfloxacin, ceftazolin T2D Survivor
   M020 61 Male B. pseudomallei Ceftriaxone, doxycycline, ceftazidime - Survivor
   M021 56 Female B. pseudomallei Ceftriaxone, ceftazidime T2D Survivor
   M022 18 Male B. pseudomallei Ceftazidime, cactrim T2D Survivor
   M023 63 Male B. pseudomallei Bactrim, ceftazidime T2D Survivor
   M024 44 Male B. pseudomallei Meropenem T2D, RF Survivor
   M025 57 Male B. pseudomallei Ceftazidime T2D Survivor
   M026 48 Male B. pseudomallei Ceftazidime, doxycycline, bactrim T2D Survivor
   M027 44 Male B. pseudomallei Ceftriaxone, ceftazidime, meropenem ARF Survivor
   M028 70 Male B. pseudomallei Ceftazidime, levofloxacin, bactrim T2D Survivor
   M029 50 Male B. pseudomallei Ceftriaxone, ceftazidime CRF Non-survivor
   M030 44 Male B. pseudomallei Ceftazidime, ceftriazone T2D, tuberculosis Survivor
  1. *Hospital-acquired septicemia;†long hospitalization;‡taken immunosuppressive drugs;§dialysis; community-acquired septicemia; ¥mechanical ventilation; ¤wounds. #Positive by two sets of blood cultures. ARF, acute renal failure; CRF, chronic renal failure; RF, renal failure; T2D, type 2 diabetes.
Back to article page

Genome Biology

ISSN: 1474-760X

Contact us